IMMPF
Price:
$0.085
Market Cap:
$15.02M
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The compan...[Read more]
Industry
Biotechnology
IPO Date
2017-02-08
Stock Exchange
PNK
Ticker
IMMPF
According to ImmuPharma plc’s latest financial reports and current stock price. The company's current PE Ratio is -2.13. This represents a change of -69.33% compared to the average of -6.93 of the last 4 quarters.
The mean historical PE Ratio of ImmuPharma plc over the last ten years is -8.86. The current -2.13 PE Ratio has changed 2.30% with respect to the historical average. Over the past ten years (40 quarters), IMMPF's PE Ratio was at its highest in in the December 2022 quarter at -0.68. The PE Ratio was at its lowest in in the December 2017 quarter at -39.20.
Average
-8.86
Median
-3.95
Minimum
-39.76
Maximum
-1.46
Discovering the peaks and valleys of ImmuPharma plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 247.09%
Maximum Annual PE Ratio = -1.46
Minimum Annual Increase = -94.31%
Minimum Annual PE Ratio = -39.76
Year | PE Ratio | Change |
---|---|---|
2023 | -2.06 | 40.84% |
2022 | -1.46 | -27.82% |
2021 | -2.03 | -47.90% |
2020 | -3.89 | -2.92% |
2019 | -4.01 | 77.12% |
2018 | -2.26 | -94.31% |
2017 | -39.76 | 247.09% |
2016 | -11.45 | 67.99% |
2015 | -6.82 | -54.08% |
2014 | -14.85 | 6.53% |
The current PE Ratio of ImmuPharma plc (IMMPF) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.85
5-year avg
-2.69
10-year avg
-8.86
ImmuPharma plc’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmuPharma plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ImmuPharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ImmuPharma plc's PE Ratio?
How is the PE Ratio calculated for ImmuPharma plc (IMMPF)?
What is the highest PE Ratio for ImmuPharma plc (IMMPF)?
What is the 3-year average PE Ratio for ImmuPharma plc (IMMPF)?
What is the 5-year average PE Ratio for ImmuPharma plc (IMMPF)?
How does the current PE Ratio for ImmuPharma plc (IMMPF) compare to its historical average?